Greetings. Welcome to Field Trip Health & Wellness Ltd. Fiscal Q2 2023 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to Phil Carlson, Managing Director of KCSA. Thank you. You may begin. Thank you, operator. Good morning, everyone, and welcome to the fiscal Q2 2023 earnings conference call for Field Trip Health & Wellness Ltd. Before I begin the call, I'm obligated to remind everyone that during the course of this conference call, management may be making some forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. These results are outlined in the Risk Factors section of the company's filings and disclosure materials. Any forward-looking statements should be considered in light of these factors. Please also note, as Safe Harbor, any outlook presented is as of today, and management does not undertake any obligations to revise any forward-looking statements in the future. Presenting today will be Ronan Levy, Chairman and CEO, Mujeeb Jafferi, President, and Donna Wong, CFO. I'll now hand the call over to Ronan, who will provide an update on Field Trip Health & Wellness. Ronan, please go ahead. Thanks, Phil, and welcome everyone. Thank you for joining us this morning. I'm pleased to provide a update on Field Trip and a more elaborate conversation on our expanded strategic direction. As you all know, Field Trip is passionate about helping people achieve improved mental health and well-being through our innovative psychedelic-assisted therapies. We are very proud of the progress we have made in pioneering the field of psychedelics and providing life-changing therapies at our clinics. Data we have gathered from our clients demonstrate its truly remarkable effectiveness. 93% of Field Trip clients have experienced a noticeable improvement in their symptoms of depression, anxiety, and trauma. On average, improving from severe to mild symptoms immediately following treatment with those improvements lasting for more than four months. As far as mental health treatments go, we are not aware of any traditional treatments achieving anywhere near this level of effectiveness. To be able to help people so profoundly in overcoming mental health conditions and live their lives free from depression, anxiety, and trauma to simply be themselves remains a core mission for Field Trip. Based on the tremendous success we have seen in our in-clinic programs and the mounting data demonstrating the impact that these psychedelic therapies have in treating mental health conditions, we have made it our new mission to expand our service offerings to make our programs more accessible. Our focus going forward is to further build upon our already robust offerings by leveraging our digital channels to achieve far greater scale. Over the past few months, we have announced several exciting new initiatives, programs, and tools that we are confident will achieve this goal. We announced the first key step in this plan in October with the launch of an updated version of our award-winning mental health and well-being app. Renaming it Field Trip is indicative of the role that this digital tool will play in our evolution going forward. It is already home to one of the largest digital communities for psychedelic therapies. We continue to add functionality, music, meditations, and content to augment the reach and power of our therapeutic offerings. We continue to innovate within the mental health space as well, launching Freedom by Field Trip this past November. The offering is a first-of-its-kind membership program that integrates the healing potential of psychedelic-assisted therapies with a variety of holistic offerings that will not only improve mental health outcomes but assist people to change the way they live to develop more emotional strength and resilience. Mujeeb will speak to these two initiatives in greater detail next. In the coming months, we are planning to launch additional programs that will further increase our ability to scale, continue to reach new audiences, and create more synergies with our existing programs. We look forward to sharing details on these shortly. On an organizational level, we recently bolstered our leadership team with the appointment of Stacey Hoisak as Senior Vice President and General Counsel, and Dr. Monique Moller as Vice President of Integrative Health. The addition of these seasoned and innovative professionals will greatly support the company as we execute on our expanded approach to mental health and well-being. I want to take a moment to recognize how significantly the regulatory landscape also continues to shift for the positive. In the recent midterm election, voters in Colorado approved the Natural Medicine Health Act. Once implemented, this will enable state legal access to a variety of psychedelic therapies. The state of Oregon has confirmed it will commence implementation of psilocybin services in early 2023. Here in Canada, the province of Alberta recently announced intentions to make psychedelic therapies, including one with psilocybin, LSD, MDMA, DMT, and mescaline available to Albertans. Finally, reports indicate that the White House has commissioned a task force to help implement the forthcoming FDA approval for MDMA and other psychedelic-assisted therapies. Field Trip is uniquely positioned with our significant clinical and digital infrastructure to capitalize upon progressing legalization. I will now hand the call over to Mujeeb to provide an update on operational highlights for the Q1 at our digital platforms. Thank you, Ronan. Good morning, everyone. Field Trip continued to deliver life-changing psychedelic-assisted therapies over the second fiscal quarter, while also expanding its offering and continuing to reduce operational costs. Field Trip's clinics business generated patient services revenue of CAD 1.8 million for the three months ended September 30th, which was 103% growth over the comparative second fiscal quarter of the prior year and consistent with the prior quarter's revenue. We achieved a cost reduction of 26.2% of recurring operating expenses over the past 12 months. The improvements in costs were driven by measures we have implemented to continually align the business towards a more sustainable capital efficient model, such as channel optimization that has reduced marketing expenses and increased automation of the client journey. We relaunched our app in October, now renamed Field Trip, which will serve as an important hub for all Field Trip service offerings and increase client engagement. The updated app includes several new features and functionality such as offline access to music and meditations, higher bitrate streaming, access to Field Trip therapeutic programs, and a new user flow. Field Trip has now been downloaded by nearly 90,000 users, signifying the growing interest in psychedelic therapies. The app relaunch was a precursor to the start of Freedom by Field Trip, our more flexible and holistic ketamine therapy subscription program that we announced in November. Freedom is a unique hybrid offering that provides members complete flexibility to participate in ketamine-assisted therapy at home or in one of Field Trip's locations. The program is divided into three chapters, with each delivered on a weekly basis to enhance the effects of the ketamine and increase neuroplasticity. It is designed to increase accessibility to psychedelic-assisted therapy and support it with a holistic approach to mental health and well-being, with meditations, nutrition classes, integration therapy, breathwork, somatic movement therapy, community talks, and membership events. Freedom by Field Trip will utilize digital channels to build community more extensively than Field Trip's previous offering. We will also leverage an... We will also leverage the app to deliver additional services to our members, including at-home ketamine therapy offerings and psychotherapy services. These operational initiatives support the evolution of the company's community-focused, digital-centric growth strategy. With our focus on scaling digital platforms, as well as measures we have enacted such as operational streamlining and improvements in digital engagement, we aim to continue to grow our reach more efficiently going forward. I will now hand the call over to Donna to discuss our financial results. Thank you, Mujeeb, and good morning, everyone. As a reminder, all figures that I will be discussing are in Canadian dollars, and the second fiscal quarter of 2023 corresponds to the three-month period ended September 30, 2022. As Mujeeb mentioned, we achieved revenues of CAD 1.8 million for the quarter, consistent with prior quarter end and 103% over the comparative second fiscal quarter of the prior year. The growth in revenue was driven by an increase of five clinics over the prior year. Net loss for the clinics in the second fiscal quarter of 2023 was CAD 14.4 million, compared with a CAD 10.7 million loss in the same period of the prior fiscal year. This increase in the net loss was primarily due to a non-cash impairment of CAD 4.9 million relating to right-of-use assets. Non-cash share-based payments of CAD 1.4 million due to the cancellation of non-vested options. CAD 1.4 million foreign exchange loss and non-recurring transaction fees of CAD 0.4 million relating to the spin-out. This was partly offset by reduced general and administration expense of CAD 3.0 million arising from continued operating efficiencies, CAD 1.0 Million and CAD 0.8 million in sales and marketing expense due to channel optimization as Mujeeb spoke to earlier. Finally, turning to the balance sheet, as at September 30th, 2020, Field Trip held approximately CAD 13.9 million in cash and working capital. This ends our prepared remarks. I'll now ask the operator to open the lines for the Q&A session. Thank you. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press Star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up the handset before pressing your star keys. Our first question is from Andrew Partheniou with Stifel. Please proceed. Hi, good morning. Thanks for taking my question. Congrats on the ability to keep the revenue up, considering this challenging environment that we're in with inflation. Thanks, Andrew. Maybe talking about, you know, Freedom by Field Trip, sorry, Freedom by Field Trip. Interesting, interesting offering here. Seems like this is kind of changing your relationship with the patient from, you know, a one-time program to kind of an ongoing recurring touchpoint throughout the year. Could you talk a little bit more about how that offering came to be? You know, was there any kind of feedback from the patients? You know, obviously taking into account the macro backdrop and inflationary environment. Sure. The development of Freedom was a result of a number of kind of converging factors. The first was, I think in terms of a general recognition of what works at enhancing one's mental health and wellbeing is that a treatment-based protocol, which we've demonstrated with our in-clinic KAP treatments, can be very effective. For sustained and lasting change, it has to be a much more integrative approach to wellness, mental, emotional, and physical wellness. Part of the rationale was just the recognition that this is the future of mental health treatments broadly, is a much more integrative approach. We wanted to lean into that. With Field Trip at Home, which was the precursor to this, we saw a lot of interest, you know, certainly just geographically and cost-wise, there are advantages to at home-based offerings. We want to lean into a deeper presence in that part. I mean, this is something that I think we've been telegraphing as part of our strategy about enhancing scale. As we looked into the broader environment, we see that there's a number of competitors offering at-home services, you know, that are hard to differentiate. We are uniquely positioned to offer a differentiated program because we have access to our in-clinic spaces as well as being able to deliver it at home. That was a factor. Also, you know, while we try to keep the cost of our services as within reach as possible for the people who need it is not inexpensive. Finding a program that enables us to offer our services at a more affordable and broken down on a monthly basis as opposed to substantially upfront, was something that, you know, our clients would resonate with. All of those were factors that went into the evolution of this program. It's unique, it's differentiated, it's, you know, cost comparable to some of the other at-home offerings, but with significantly enhanced value by virtue of the additional services and the access to our in-clinic spaces as well. Does that specifically answer your question, or is there anything else you wanted me to touch on? No. That definitely addresses the question. Thank you. Maybe just a follow on to that. I mean, it kind of sounds like this could be going forward, you know, or rather over time going to be the main revenue driver for the company. Sounds like you're gonna, you know, dedicate more resources towards this offering because it seems to be a little bit better for your patients, more flexibility. Is that a fair assessment? It is definitely going to be, you know, the near term focus, creating awareness for it because it is a differentiated program. Articulating the advantages of it, I think is something that's going to require some investment. Certainly, our existing KAP treatments are working incredibly well for people, but I think they're more suited to being promoted and creating awareness in terms of a peer-to-peer, clinician-to-clinician kind of offering, where this is a little bit more consumer focused. There's definitely going to be an emphasis on it on the short to medium term. You know, if and when you have the chance to visit the website, you'll see that if you choose to start a program, you'll see that the intake process starts the same way, and then people will naturally self-separate into whether they want to go at home or work with a hybrid approach. You know, we'll get I think an incredible amount of data and the interest, and then we'll obviously be responsive as we get more data and understand what is motivating people to make treatment decisions. Makes sense. Maybe switching gears. I remember some time ago, you know, you guys discussed about the profitability of some of your earlier clinics or your oldest clinics. Just wanted to get an update on how that's trending. Any kind of color that you're comfortable to provide. Mujeeb, do you wanna speak to that? Sure. Hey, Andrew. Good morning. I think we've sort of resisted from giving clinic-level profitability numbers, but I think it still is consistent with what spoke about in the past, which was some of our older clinics are profitable or near profitability, while the others that have opened recently still need a bit of work that still needs to be done. I think having a program like Freedom by Field Trip, that program I think is really gonna help sort of increase scale and create a bit more of a recurring revenue program, and really lean into that group programming aspect of it. This would be pretty additive going forward to some of the clinics that may be more recent. Perfect. Thank you. Johan, maybe a last question for me, or I guess this is more of a two-part question. You know, you touched on a little bit on Oregon and Alberta. Definitely a interesting dynamic there. You know, how do you see Oregon playing out, and do you see any specific opportunities for yourselves within that new market? And similarly in Alberta, is this kind of just a, you know, a similar situation to Oregon, but with a wider variety of psychedelics? How should we think about the opportunity in Alberta? You know, is there anything that we can look to in order to, you know, gauge the level of progression within those two jurisdictions? Entirely fair question. We continue to evaluate opportunities in Oregon as to the best approach, also with a view to navigating any particular regulatory considerations. You know, as we saw with the cannabis industry, the federal versus state legality issues create conversations for publicly traded companies and those are conversations we're still navigating. We can't provide any definitive commentary on Oregon at this moment other than to say we continue to evaluate and try to understand the best opportunities to approach. Alberta is I think an interesting evolution in the broader legalization and regulatory landscape. The announcement I think caught most people off guard, and it also was lacking in what I think many would view to be essential details about supply, access, prescribing conditions. You know, there's a number of things that need to be baked out. I haven't heard any further updates on that program since. I think what stands out to me about that program is the shifting political perspectives towards psychedelics. This was a unilaterally implemented move by the province of Alberta, unlike Colorado and Oregon, which was implemented through voter efforts. This was political and regulatory. I think that's a very favorable sign along with the task force that the White House is initiating to explore implementation of MDMA-assisted and other psychedelic-assisted therapies. I take them more as a sign towards shifting attitudes, broadly speaking, that would reflect an adoption that I would consider to be accelerated relative to what we saw with cannabis. In terms of markers of success for Oregon, it's a good question. You know, we're just taking a wait and see approach. I do anticipate, much like we saw with the cannabis industry, is that there's gonna be bumps and hiccups along the way as the regulatory system gets figured out. That's why we're happy to be strategic in our approach to, you know, Oregon and probably subsequently Colorado as some of the nuances of new regulatory regimes gets worked out. Appreciate that color and definitely interesting, out of all provinces, it is Alberta that took this stance. Thought that was interesting. Yeah. I'll get back in the queue. Thanks, Andrew. As a reminder to star one on your telephone keypad, if you would like to ask a question. We will just pause for a brief moment for any final questions. There are no more questions at this time. I would like to turn the conference back over to management for closing comments. Thank you, operator. Thank you to all who joined us today. Andrew, thank you specifically for your questions. I'd like to thank our investors and the analysts in particular for the ongoing support. We want to equip people to change their lives as well as their minds. Through our innovative programs of psychedelic-assisted therapies as well as our digital tools, we can equip people to work through anxiety, depression, trauma, and dive deeper into self-discovery and self-awareness. Field Trip is well-placed to thrive and lead in the burgeoning psychedelic space as we scale to reach more people and build our communities further. Thank you again for your continued interest in Field Trip. I will now ask the operator to close the lines. Thank you. This does conclude today's conference. You may disconnect your lines at this time, and thank you for your participation.